A US Hospital-Perspective Decision-Analytic Model of Once-Weekly Rezafungin Versus Daily Echinocandin Therapy in Hospitalized Adults With Candidemia or Invasive Candidiasis: Potential Cost Savings From Earlier Discharge

Clicks: 17
ID: 328334
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #220 of 318 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 318 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Hospitalized adults with candidemia or invasive candidiasis (C/IC) often remain inpatient to complete daily intravenous echinocandin therapy. Rezafungin, a once-weekly echinocandin, may facilitate earlier discharge in clinically stable patients. We evaluated its potential economic impact from a US hospital perspective. Methods A decision-analytic probabilistic model compared two treatment-discharge strategies in 100 hypothetical hospitalized adults with candidemia or invasive candidiasis (C/IC) who had reached clinical stability and were otherwise dischargeable: continued inpatient daily echinocandin therapy until observed discharge versus administration of a single 400 mg dose of rezafungin with earlier discharge. The rezafungin strategy incorporated earlier discharge distributions from a multicenter US study. Costs included antifungal acquisition, inpatient hospitalization during the final 4 hospital days, and PICC-related costs (2026 US dollars). Deterministic, threshold, and probabilistic sensitivity analyses (10,000 Monte Carlo simulations) were performed, focusing on excess hospital costs. Results In the base case, mean excess cost was lower with rezafungin than standard of care (SOC) (−$412 vs $708 per patient), corresponding to savings of $1,120 per patient. Savings were greater when SOC required PICC placement (−$2,269) versus no PICC placement (−$851). Rezafungin was associated with higher costs when no earlier discharge occurred (+$3,471) or discharge occurred only 1 day earlier (+$1,475), but became cost saving with ≥2 days earlier discharge (−$556 at 2 days, −$2,903 at 3 days, and −$5,313 at ≥4 days). Conclusions Once-weekly rezafungin reduced hospital costs versus daily echinocandins when it enabled discharge ≥2 days earlier, with greater savings when PICC placement was avoided.
Reference Key
openalex_W7212055067 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Thomas P. Lodise, Nimish Patel
Are you one of these authors? Claim your profile
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag563
URL
https://doi.org/10.1093/ofid/ofag563
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.